TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02941497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social marketing and health promotion campaign
Description: Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
Study: NCT01216982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, visually identical to Lovaza
Description: Three 1g corn oil capsules/day for three months
Study: NCT00850720

Intervention type: OTHER
Intervention: Blood draws
Description: Samples of blood to be drawn before surgery, and nine hours after surgery.
Study: NCT01482949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Autologous Dendritic Cell Immunotherapy
Study: NCT03615209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transauricular vagus nerve stimulation
Description: Stimulation will be performed for 150 minutes (throughout the entire OGTT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transauricular sham stimulation
Description: Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
Study: NCT03167216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Mast cell stabilizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride
Description: Histamine receptor antagonist
Study: NCT04441424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: 400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquin with Azithromycin
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquin with Azithromycin
Description: The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.
Study: NCT01521325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amatuximab
Description: Subjects will receive one infusion of radiolabeled amatuximab.
Study: NCT01058330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric training program
Description: The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of five lower extremity exercises and five upper extremity exercises
Study: NCT04299802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte-Rich Platelet-Rich Plasma
Description: LR-PRP will be a concentration of PRP with the addition of leukocytes. Studies have shown that LR-PRP is more effective in treating tendinopathy than leukocyte-poor platelet-rich plasma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Ultrasonic Tenotomy
Description: Discussed in Percutaneous Ultrasonic Tenotomy Arm section
Study: NCT02476097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole: Nexium® 20mg, Astra Zeneca
Description: Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19 phenotypical analysis
Description: All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CYP2C19 phenotypical analysis
Description: All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
Study: NCT02814110

Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte colony-stimulating factor (Filgrastim)
Description: Drug administration
Study: NCT04719936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior capsulotomy
Description: inferior capsulotomy will be conducted during posterior approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superior capsulotomy
Description: superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
Study: NCT03478995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: GX-I7 25mg/ml/vial
Study: NCT00974935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEBVax vaccine
Description: Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
Study: NCT01978743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
Study: NCT04327128

Intervention type: DEVICE
Group type: OTHER
Intervention: LifePod
Description: The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifePod
Description: The intervention group is testing LifePod on a digital communication platform between patient and healthcare provider
Study: NCT02606708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated intensity modulated radiation therapy (AIMRT)
Study: NCT00897377

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT03450057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab with dexamethasone
Description: Daratumumab:~Daratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).~Dexamethasone:~Dexamethasone was administered at 40 mg (20 mg for patients \>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
Study: NCT03656367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cheddar cheese
Description: The reference product is a commercial matured cheddar cheese

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cheddar cheese
Description: The reference product is a commercial matured cheddar cheese
Study: NCT00714142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET Scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: PET Scan
Study: NCT01880346

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Powder
Description: Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
Study: NCT03656367

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blended and homogenized cheddar cheese
Description: A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Blended and homogenized cheddar cheese
Description: A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An analog milk
Description: An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: An analog milk
Description: An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An analog cheese
Description: This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: An analog cheese
Description: This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
Study: NCT00510172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostacyclin, PGI2
Description: 10 ng/kg/min of epoprostenol (stable PGI2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCL 0,9%
Study: NCT01010932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOF MRA
Description: Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
Study: NCT03692663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TABP EIC
Description: A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
Study: NCT03976635

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Mandibular Retractor
Description: The appliance will be used 18 hours per day. It can only be removed for eating meals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-anchored intermaxillary traction
Description: The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
Study: NCT00001703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: 0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
Study: NCT03308578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
Study: NCT00655551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
Study: NCT01880346

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Oil
Description: Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
Study: NCT01855438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Donor Transplant Education
Description: The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Donor Transplant Education
Description: The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
Study: NCT01418872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Concerts
Description: The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Concerts
Description: The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered.
Study: NCT05203627

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard nutritional support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Visit
Description: Receive telehealth sessions
Study: NCT00405041

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement GVG 2
Description: 2.670 g/day for 14 days
Study: NCT01701791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System
Study: NCT02306278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: gabapentin capsules 0.3g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vitamin capsules
Description: vitamin B
Study: NCT03644576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozanimod
Description: ozanimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Pseudoephedrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ozanimod placebo
Description: ozanimod placebo
Study: NCT05049785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Attend nutrition counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete PA sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive nutrition handouts

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Attend tasting sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03116113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.
Study: NCT01011257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asprin
Description: asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel 75 mg bid